Document Type
Blog Post
Publication Date
10-19-2015
Disciplines
Nervous System Diseases
Digital USD Citation
Serbin, Kenneth P., "Huntington’s disease patients get first dosing in historic Isis Pharmaceuticals' gene-silencing drug trial" (2015). At Risk for Huntington's Disease. 214.
https://digital.sandiego.edu/huntingtons/214
